Leerink Partners Cuts Price Target on Aegerion Pharma (AEGR) Following 1Q Miss and Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Aegerion Pharmaceuticals Announces First Quarter 2016 Financial Results
May 16, 2016 4:05 PM EDTCompany records $35.7 million in total net product sales    Company now expects full-year revenues for JUXTAPID to be between $90 million and $100 millionCompany continues to expect full-year revenues for MYALEPT to be between $40 million and $50 million
CAMBRIDGE, Mass., May 16, 2016 (GLOBE NEWSWIRE) -- Â Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business... More
